Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing hair regrowth using a combination of oral finasteride, a minoxidil/finasteride topical spray, and dermarolling. They plan to continue this regimen and may consider adding dutasteride if needed.

The conversation discusses whether to take oral minoxidil in a split dose or a single dose at night. Users suggest that taking a single 10mg dose at night is simpler, while splitting may help minimize side effects.

Minoxidil can prevent hair follicle miniaturization, not just stimulate hair growth. Finasteride and dutasteride don't work for everyone, suggesting DHT may not be the sole cause of hair loss; hair loss could be due to multiple factors, including autoimmune conditions.

Minoxidil, finasteride, and RU58841 promote hair growth by different mechanisms, with minoxidil and prostaglandin E1 being specifically mentioned. Corticosteroids can also cause hair growth.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

PRP therapy cannot make oral minoxidil's effects permanent, as minoxidil does not stay permanently in the system. Dosage of oral minoxidil is typically increased gradually, but there is a limit, and it should not be increased indefinitely.

The user is mixing various topical solutions for hair loss, including Dutasteride, Minoxidil, Finasteride, tretinoin, RU58841, Stemoxydine, and Reviv AHK-Cu, and is questioning if this practice is effective or wasteful. They are concerned about potential interactions, especially with the new treatment KX-826, which should not be mixed with Minoxidil.

Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.

A 21-year-old experiencing significant hair loss is considering a hair transplant and has been using finasteride and biotin, with plans to switch to dutasteride and oral minoxidil for better regrowth. They are seeking advice on the number of grafts needed, with suggestions ranging from 2,500 to 6,000, and are exploring different clinics and treatment options.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

The user switched from Hims topical finasteride and minoxidil to Musely Hair Pill Bloom+, which includes minoxidil, dutasteride, and other vitamins, and noticed new hair growth but also experienced lower blood pressure. Another user ordered a minoxidil-only pill.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The user has been using minoxidil, finasteride, and microneedling for two years, resulting in significant hair regrowth and plans for a 4000 graft hair transplant. The treatments have strengthened the donor area, making a hair transplant feasible.

A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A user shared their positive experience with hair regrowth using minoxidil, hormone replacement therapy, and cyproterone acetate during their male-to-female transition. Another user discussed their successful hair transplant after transitioning and using finasteride, highlighting the challenges of hair loss and regrowth during transition.

The conversation is about the effectiveness of Minoxidil formulations with different alcohol and propylene glycol (pg) ratios. The user finds that a formulation with 20% pg and 80% ethanol dries faster but is concerned about absorption time.

Minoxidil can be effectively delivered through nanoemulsions containing eucalyptol or oleic acid, enhancing its diffusivity and targeting hair follicles. This contradicts the advice against mixing minoxidil with oils in topical formulations.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The conversation discusses "Hair bloom" hair filler, which contains biotin, collagen, and various peptides, as a potential alternative to PRP or mesotherapy for hair loss. Opinions vary, with some suggesting it may be a cash grab or ineffective, while others believe it could complement topical minoxidil for early hair loss.

Minoxidil sulfate is more effective than regular minoxidil, especially for those with low sulfotransferase levels or scalp sensitivity, but it is unstable unless delivered in a liposomal format. Combining minoxidil with tretinoin can enhance effectiveness, and stopping minoxidil use can lead to rapid hair loss.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

A user is creating a custom topical hair regrowth serum using minoxidil, bimatoprost, tretinoin, castor oil, and hyaluronic acid. They are also using dutasteride, oral minoxidil, and castor oil in their current regimen.

A user underwent a hair transplant with 3200 grafts and plans to update others on their progress. They previously used minoxidil and finasteride to stabilize hair loss but opted for a transplant for better results.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.